Assignee
ARROWHEAD PHARMACEUTICALS INC
US·76 granted patents·81 pending applications·153 citations·filing 2016–2025
Top patents by PatentIndex Score
157 records- 0196US10450565B2Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Oct 22, 2019·15 cites·39 claims
- 0296US10130651B2RNAi Therapy for Hepatitis B Virus InfectionARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Nov 20, 2018·22 cites·18 claims
- 0395US11884920B2Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Jan 30, 2024·2 cites·21 claims
- 0495US9932586B2Compositions and methods for inhibiting gene expression of LPAARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Apr 3, 2018·9 cites·39 claims
- 0594US12188017B2Compositions and methods for inhibiting gene expression of alpha-1 antitrypsinARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Jan 7, 2025·1 cites·12 claims
- 0694US11517584B2RNAi agents for Hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 6, 2022·2 cites·58 claims
- 0794US11214801B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Jan 4, 2022·3 cites·30 claims
- 0893US10662427B2Compositions and methods for inhibiting gene expression of LPAARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted May 26, 2020·6 cites·39 claims
- 0993US10597657B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 24, 2020·6 cites·51 claims
- 1092US11629349B2RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Apr 18, 2023·3 cites·14 claims
- 1192US11590156B2RNAi agents for hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Feb 28, 2023·2 cites·37 claims
- 1292US11549112B1RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Jan 10, 2023·3 cites·14 claims
- 1392US11203756B2Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Dec 21, 2021·5 cites·25 claims
- 1492US10780108B2RNAi agents for Hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Sep 22, 2020·5 cites·67 claims
- 1592US10294474B2Targeting ligandsARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted May 21, 2019·15 cites·50 claims
- 1692US10246709B2Targeting ligands for therapeutic compoundsARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Apr 2, 2019·10 cites·27 claims
- 1791US11384355B2Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsinARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Jul 12, 2022·3 cites·23 claims
- 1890US10240153B2Organic compositions to treat APOC3-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Mar 26, 2019·7 cites·17 claims
- 1990US2025197861A1Compositions and methods for inhibiting gene expression of alpha-1 antitrypsinARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2089US11174481B2Targeting ligandsARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Nov 16, 2021·3 cites·4 claims
- 2189USRE48345ECompositions and methods for inhibiting gene expression of hepatitis B virusARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Dec 8, 2020·3 cites·69 claims
- 2289US10806750B2RNAi therapy for hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Oct 20, 2020·3 cites·9 claims
- 2387US10308941B2Compositions and methods for inhibiting gene expression of factor XIIARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Jun 4, 2019·4 cites·26 claims
- 2487US2025243485A1Targeting Ligands For Therapeutic CompoundsARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2586US11845937B2RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2023·Granted Dec 19, 2023·1 cites·22 claims
- 2686US11180529B2Alpha-v beta-6 integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Nov 23, 2021·3 cites·18 claims
- 2786US10927373B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Feb 23, 2021·2 cites·20 claims
- 2886US10287582B2Organic compositions to treat HSF1-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted May 14, 2019·3 cites·18 claims
- 2986US2025115907A1Compositions and methods for inhibiting gene expression of lpaARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3085US12365899B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Jul 22, 2025·0 cites·22 claims
- 3185US2026043025A1RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3285US2022364097A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3384US2024141351A1Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3483US12091661B2Organic compositions to treat HSF1-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Sep 17, 2024·0 cites·20 claims
- 3583US10995335B2RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted May 4, 2021·3 cites·19 claims
- 3683US2025270555A1Organic compositions to treat beta-catenin-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3783US2022162614A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3882US11597701B2Integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 7, 2023·2 cites·24 claims
- 3982US2022235361A1RNAi Inhibition of Alpha-ENaC ExpressionARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4082US2022042021A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4181US10590416B2RNAi agents for inhibiting expression of alpha-ENaC and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 17, 2020·1 cites·52 claims
- 4281US10544418B2RNAi inhibition of alpha-ENaC expressionARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Jan 28, 2020·1 cites·13 claims
- 4381US2022112505A1RNAi Inhibition of Alpha-ENaC ExpressionARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4480US12110492B2RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2023·Granted Oct 8, 2024·0 cites·14 claims
- 4580US2023355651A1Rnai agents for hepatitis b virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4679US12378558B2RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2024·Granted Aug 5, 2025·0 cites·19 claims
- 4779US2021230603A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4879US2023355654A1Rnai therapy for hepatitis b virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4979US2021108206A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 5078US9752152B2Organic compositions to treat beta-ENaC-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Sep 5, 2017·1 cites·15 claims
Showing the top 50 of 157 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ARROWHEAD PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →